Prime Medicine (PRME) said Monday that it has entered into a strategic research collaboration and license agreement with Bristol Myers Squibb (BMY) to develop reagents for the next generation of ex vivo T-cell therapies.
The company said it will receive a $55 million upfront payment and a $55 million equity investment from Bristol Myers Squibb, and will also be eligible to receive over $3.5 billion in milestones.
Prime Medicine will design optimized Prime Editor reagents for a select number of targets, while Bristol Myers Squibb will be responsible for the development, manufacturing, and commercialization of the next-generation cell therapies, the company said.
Prime Medicine's share price jumped almost 14% in recent Monday premarket activity.
Price: 3.94, Change: +0.48, Percent Change: +13.87
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。